Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Total Stockholders’ Equity (Deficit) Attributable to the Company	Common Stock	Preferred Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interests	Class A Common Stock Common Stock	Class B Common Stock Common Stock
Beginning balance (in shares) at Dec. 31, 2023									1,060,833	6,667
Beginning balance at Dec. 31, 2023	$ 228,236				$ 4,180,873	$ 5,862	$ (3,958,499)		$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of notes payable and accrued interest into Class A Common Stock (in shares)									62,101,798
Conversion of notes payable and accrued interest into Class A Common Stock	226,341				226,335				$ 6
Reclassification of SPA Warrants from liability to equity	160				160
Settlements with issuance of Class A Common Stock (in shares)									1,080,294
Settlements with issuance of Class A Common Stock	4,800				4,800
Issuance of common stock and warrants	10				10
Purchase of Class A Common Stock under Salary Deduction and Stock Purchase Agreements (in shares)									49,659
Purchase of Class A Common Stock under Salary Deduction and Stock Purchase Agreements	102				102
Grow Fandor Contribution	250				250
Related party debt restructuring	661				661
Reverse stock split related round up share issuances (in shares)									306,779
Stock-based compensation	8,382				8,382
Issuance of shares for RSU vesting net of tax withholdings (in shares)									1,319,764
Issuance of shares for RSU vesting net of tax withholdings	(10)				(10)
Foreign currency translation adjustment	1,882					1,882
Net loss	(355,847)						(355,847)
Ending balance (in shares) at Dec. 31, 2024				0					65,919,127	6,667
Ending balance at Dec. 31, 2024	114,967	$ 114,967		$ 0	4,421,563	7,744	(4,314,346)	$ 0	$ 6	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of notes payable and accrued interest into Class A Common Stock (in shares)				(7,536,154)					124,111,566
Conversion of notes payable and accrued interest into Class A Common Stock	189,962	189,962		$ 25,400	189,949				$ 13
Issuance of preferred stock series B to SPA noteholders (in shares)				14,720,914
Reclassification of SPA warrants from liability to equity (in shares)				0
Reclassification of SPA Warrants from liability to equity	7,134	7,134			7,134
Settlements with issuance of Class A Common Stock (in shares)									1,320,722
Settlements with issuance of Class A Common Stock	1,833	1,833			1,833
Issuance of equity-classified warrants	1	1			1
Related party debt restructuring	3,767	3,767			3,767
Cancellation of warrants	27,407	27,407			27,407
Stock-based compensation	447	447			447
Exercise of warrants (in shares)									7,516,026
Exercise of warrants	21,693	21,693			21,691				$ 2
Sell-to-cover tax withholding on equity awards (in shares)			12,069
Issuance of shares for RSU vesting net of tax withholdings (in shares)									251,217
Issuance of shares for RSU vesting net of tax withholdings	74	74			74
Foreign currency translation adjustment	(3,927)	(3,927)				(3,927)
Net loss	(397,082)	(390,696)					(390,696)	(6,386)
Noncontrolling interest - business combination	31,584							31,584
Noncontrolling interest - capital contribution	9,899							9,899
Ending balance (in shares) at Dec. 31, 2025				7,184,760					199,130,727	6,667
Ending balance at Dec. 31, 2025	$ 7,759	$ (27,338)		$ 0	$ 4,673,866	$ 3,817	$ (4,705,042)	$ 35,097	$ 21	$ 0